Dr. Reddy's and Prestige BioPharma announce partnership to commercialize biosimilar for cancer treatment in select countries in Latin America and Southeast Asia

Author's Avatar
Dec 15, 2021

Prestige BioPharma and Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, hereafter referred to as “Dr. Reddy’s”) today announced that the two companies have entered into a binding agreement for an exclusive partnership for the supply and commercialization of Prestige BioPharma’s proposed biosimilar for the treatment of cancer in select countries in Latin America and Southeast Asia.